Loading...

COYA COYA THERAPEUTICS INC US FDA Inspections 8-K Filing

CY T

CY

COYA THERAPEUTICS INC

(COYA)

2026 8-K

Sales Agreement Details

FDA Fast Track Designation

Director Resignation

Operational Results Report

Stock Offering Announcement

Financial Update

Positive Study Results

Milestone Payment Received

Financial Update

Stock Offering Launch

Milestone Payment

Clinical Trials

Clinical Trials

Earnings Releases

Financial Results

Quarterly Results

Director Resignation

Management Changes

Clinical Trial Results

Management Change

Quarterly Results

Other Special Situation

Agreement Amendment

Securities Purchase Agreement

Earnings Reports

Results of Operations and F...

Quantitative Data

Development and License Agr...

Results of Operations and F...

Earnings Report

Quantitative Data

Quantitative Data

Quantitative Data

Quantitative Data

Earnings Reports

Earnings Reports

License Agreement with Dr. ...

Conference Call for ALS Cli...

Banking Relationship

Equity Compensation Grants

External Links:

On May 11, 2026, Coya Therapeutics, Inc. announced that the U.S. FDA granted Fast Track Designation to COYA 302 for treating ALS, aiming to expedite its development.

AI Assistant

COYA THERAPEUTICS INC

2026

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.